Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease treatments, will release its Q2 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. Investors can access the webcast through Liquidia's website, where it will remain archived for one year.
Liquidia Corporation (NASDAQ: LQDA), un'azienda biofarmaceutica specializzata in trattamenti per malattie cardiopolmonari rare, pubblicherà i suoi risultati finanziari del secondo trimestre 2025 martedì 12 agosto 2025. La società terrà una trasmissione in diretta web alle 8:30 ora della costa orientale per discutere i risultati e fornire un aggiornamento aziendale. Gli investitori potranno accedere alla trasmissione tramite il sito web di Liquidia, dove resterà archiviata per un anno.
Liquidia Corporation (NASDAQ: LQDA), una compañía biofarmacéutica centrada en tratamientos para enfermedades cardiopulmonares raras, publicará sus resultados financieros del segundo trimestre de 2025 el martes 12 de agosto de 2025. La empresa realizará una transmisión en vivo a las 8:30 a.m., hora del Este para discutir los resultados y ofrecer una actualización corporativa. Los inversores podrán acceder a la transmisión a través del sitio web de Liquidia, donde permanecerá archivada durante un año.
Liquidia Corporation (NASDAQ: LQDA)는 희귀 심폐 질환 치료에 중점을 둔 바이오제약 회사로, 2025년 8월 12일 화요일에 2025년 2분기 재무 실적을 발표할 예정입니다. 회사는 동부 표준시 오전 8시 30분에 웹캐스트를 개최하여 실적을 논의하고 기업 현황을 업데이트할 예정입니다. 투자자들은 Liquidia 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 해당 웹캐스트는 1년간 아카이브로 보관됩니다.
Liquidia Corporation (NASDAQ : LQDA), une société biopharmaceutique spécialisée dans les traitements des maladies cardiopulmonaires rares, publiera ses résultats financiers du deuxième trimestre 2025 le mardi 12 août 2025. La société organisera une webdiffusion à 8h30, heure de l'Est pour discuter des résultats et fournir une mise à jour d'entreprise. Les investisseurs pourront accéder à la webdiffusion via le site web de Liquidia, où elle restera archivée pendant un an.
Liquidia Corporation (NASDAQ: LQDA), ein biopharmazeutisches Unternehmen, das sich auf die Behandlung seltener kardiopulmonaler Erkrankungen spezialisiert hat, wird seine Finanzergebnisse für das zweite Quartal 2025 am Dienstag, den 12. August 2025 veröffentlichen. Das Unternehmen wird um 8:30 Uhr Eastern Time ein Webcast veranstalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Investoren können über die Website von Liquidia auf den Webcast zugreifen, der dort ein Jahr lang archiviert bleibt.
- None.
- None.
MORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA™ (treprostinil) inhalation powder, a drug that has been approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
When will Liquidia (NASDAQ: LQDA) report Q2 2025 earnings?
What time is Liquidia's Q2 2025 earnings call?
How can investors access Liquidia's Q2 2025 earnings call?
What does Liquidia Corporation (LQDA) do?
